High-Risk APL (WBC >10,000/ml): Next Step When Salvage Therapy Fails to Restore Molecular Remission
This protocol addresses patients with high-risk acute promyelocytic leukemia — defined by a white blood cell count above 10,000/ml — who have received salvage therapy for relapsed or refractory disease but have not regained the required molecular complete remission.
Clinical Scenario — High-Risk APL
High-risk APL is defined by a WBC count above 10,000/ml at presentation. In the ATRA era, APL is stratified by WBC: high-risk (>10,000/ml), intermediate-risk, and low-risk — though most clinicians today use two categories: high-risk and low/intermediate-risk.
Previous Therapy — Failure Condition
Salvage therapy for relapsed or refractory disease was administered. This may have included arsenic trioxide combined with idarubicin or gemtuzumab ozogamicin, ATRA combined with arsenic trioxide, single-agent gemtuzumab ozogamicin, or tamibarotene combined with arsenic trioxide.
The required goal was not reached:
- Regaining of molecular complete remission (PML-RARA negative) was not achieved.
This failure is the trigger for the current protocol.
What Comes Next
Consolidation of a second remission in this setting centres on stem cell transplantation — the specific pathway depends on the patient's molecular response status at the time of planned transplant.
References
DOI: 10.3389/fonc.2022.1062524
- In the era of ATRA, APL has been stratified into three categories of risk with regards to relapse-free survival (RFS): WBC >10,000/ml (high-risk), WBC ≤10,000 ml with platelet count ≤40,000/ml (intermediate-risk), and WBC ≤10,000/ml with platelet count >40,000/ml (low-risk).
- Today, most clinicians will categorize APL within two categories, high risk (>10,000/ml) and low/intermediate risk.
- In summary, ATO-based induction with consolidation either with autologous or allogeneic SCT for patients with MRD negativity or positivity, respectively, remains the recommended treatment for patients in first relapse, with extended ATO consolidation and GO as a single or combination agent remaining a reasonable option for patients who cannot or prefer not to undergo SCT.
- PCR-positivity for PML-RARa at the time of autologous SCT appears to be a strong predictor of post-transplant relapse; allogeneic SCT is therefore a reasonable consideration in those patients unable to reach a complete molecular response ahead of planned transplantation.
View source ↗